ArticleJournal of the Chinese Medical Association : JCMA2025
Incidence and characteristics of Guillain-Barré syndrome in Taiwan before and during the COVID-19 pandemic: A 12-year single-center experience.
Article in Journal of the Chinese Medical Association : JCMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of vitamin D for COVID-19.Journal of the Chinese Medical Association : JCMA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is substantial regional disparity in the presentation of Guillain-Barré syndrome (GBS), and coronavirus disease 2019 (COVID-19) possibly influences the development of GBS, but the association remains uncertain. This study aimed to investigate the incidence of GBS before and during the COVID-19 pandemic and delineate the clinical profile of GBS in Taiwanese patients.
methodsMedical records of 185 ascertained GBS cases at Taipei Veterans General Hospital between 2011 and 2022 were reviewed. Patients were analyzed based on age, clinical subtypes, and electrophysiological findings. A multivariable ordinal logistic regression was conducted to identify factors related to outcomes measured by the GBS disability scale (GBS-DS), which ranges from 0 to 6, with higher scores indicating greater disability.
resultsThe single-center incidence (SCI) of GBS, defined as the number of GBS cases relative to the total number of outpatient and emergency department visits per year, remained stable during the COVID-19 pandemic (14.3 cases per year) compared with the prepandemic period (15.8 cases per year). COVID-19 infection or vaccination was reported as a preceding event in six cases, five of which had good outcomes (GBS-DS ≤2). In our cohort, 12% were diagnosed with Miller-Fisher syndrome (MFS), 13% had GBS/MFS overlap, and the remaining patients had typical GBS. One-third had axonal GBS, associated with significantly worse outcomes compared with demyelinating GBS. The overall mortality rate was 1.1%. Old age, low Medical Research Council sum score, ventilator dependency, and autonomic dysfunction were independent predictors of high GBS-DS scores.
conclusionThis single-center study found no increase in GBS occurrence during the COVID-19 pandemic. In Taiwan, GBS is characterized by a higher occurrence of MFS and GBS/MFS overlap and more frequent axonal GBS, highlighting geographical variations in GBS features between Asian and Western countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.